Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Medicinova Inc (NQ: MNOV)
9.860 USD  -0.070 (-0.70%)
Official Closing Price  /  Updated: 5:24 PM EST, Nov 16, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 44,500
Open 9.790
Bid (Size) 9.860 (27)
Ask (Size) 9.870 (2)
Prev. Close 9.930
Today's Range 9.670 - 10.06
52wk Range 6.085 - 14.50
Shares Outstanding 41,129,073
Dividend Yield N/A
Performance
YTD
+49.39%
+49.39%
1 Month
-8.53%
-8.53%
3 Month
+9.80%
+9.80%
6 Month
-0.20%
-0.20%
1 Year
+50.76%
+50.76%
Top News
More News
MediciNova Announces FDA Grants Orphan Drug Designation to MN-166 (ibudilast) for Glioblastoma
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that the U.S. Food... Read More
from GlobeNewswire News Releases
MediciNova Announces Positive FDA Feedback Regarding Phase 3 Plan for MN-166 (ibudilast) in ALS
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received... Read More
from GlobeNewswire News Releases
More News
Read More
MediciNova to Present at the Ladenburg Thalmann 2018 Healthcare Conference in New York
from GlobeNewswire News Releases
MediciNova to Attend the Morgan Stanley Global Healthcare Conference in New York
from GlobeNewswire News Releases
MediciNova Announces the Publication of Results of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS in the New England Journal of Medicine
from GlobeNewswire News Releases
National Institute on Alcohol Abuse and Alcoholism Awards R01 Research Grant to UCLA for Phase 2b Clinical Trial of MediciNova's MN-166 (ibudilast) in Alcohol Use Disorder
from GlobeNewswire News Releases
Report: Exploring Fundamental Drivers Behind MediciNova, Dermira, FRP, BiondVax Pharmaceuticals, The Descartes Systems Group, and American Software — New Horizons, Emerging Trends, and Upcoming Develo
from GlobeNewswire News Releases
MediciNova Announces Initiation of NIHR Grant-Funded Phase 2/3 Trial of MN-166 (ibudilast) for the Treatment of Degenerative Cervical Myelopathy in Collaboration with the University of Cambridge
from GlobeNewswire News Releases
MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 29th International Symposium on ALS/MND in Glasgow, Scotland, UK
from GlobeNewswire News Releases
MediciNova Announces Full Enrollment in ALS Biomarker Clinical Trial
from GlobeNewswire News Releases
Commit To Buy Medicinova At $7.50, Earn 17.4% Annualized Using Options
category Stocks
from Market News Video
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.